Comparative Pharmacology
Head-to-head clinical analysis: HY PAM 25 versus SALUTENSIN DEMI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HY PAM 25 versus SALUTENSIN DEMI.
HY-PAM "25" vs SALUTENSIN-DEMI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.
Salutensin-Demi is a combination of hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption, and reserpine, an adrenergic neuron-blocking agent that depletes catecholamines from peripheral nerve endings, reducing sympathetic outflow.
25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.
1 tablet (15 mg hydrochlorothiazide + 0.075 mg clonidine) orally once daily, with titration based on blood pressure response.
None Documented
None Documented
Terminal elimination half-life 6-8 hours in healthy adults; prolonged to 12-18 hours in renal impairment (CrCl <30 mL/min) and in elderly patients.
Hydrochlorothiazide: 6-15 hours (terminal), clinical effect lasts 6-12 hours; Reserpine: 50-100 hours (terminal), with prolonged action due to irreversible vesicular depletion
Primarily renal (60-70% unchanged drug), with 30-40% biliary/fecal elimination as metabolites.
Renal: hydrochlorothiazide 70% unchanged, reserpine <1% unchanged; fecal: reserpine ~6% as metabolites
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination